2:45 PM
 | 
May 12, 2017
 |  BioCentury  |  Strategy

Vertical vision

How Shire’s Parion deal adds to its ophthalmics pipeline

Shire plc’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia.

On May 1, Shire gained exclusive, worldwide rights to P-321 ophthalmic solution, an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease.

The candidate is Shire’s second for dry eye; it launched Xiidra lifitegrast in September. Shire gained that drug, then in Phase III testing, via the 2013 acquisition of SARcode Bioscience Inc.

Shire hasn’t decided yet how P-321 will slot alongside Xiidra, but it believes having another molecule in dry eye with a novel MOA will be complementary.

“If you want to be a market leader in any therapeutic area, you need to have different treatment options for different patients.”

Perry Sternberg, Shire

According to BioCentury’s BCIQ online database, P-321 is the only ENaC inhibitor in the clinic for dry eye.

ENaC is a protein found on the surface of the eye and many other tissues. On the surface of the eye, it regulates the intake of sodium...

Read the full 902 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >